<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rizzo, Toni</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">George, Jyothis T.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">LH and Testosterone Significantly Reduced With NKB Receptor Antagonist in PCOS</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-05-18 15:35:55</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">16-17</style></pages><abstract><style  face="normal" font="default" size="100%">Luteinizing hormone and testosterone levels were significantly decreased by treatment with the neurokinin B receptor antagonist AZD4901 80 mg compared with placebo in women with polycystic ovary syndrome. The reductions were maintained throughout the 28 days of treatment. AZD4901 was safe and well tolerated in this group of patients.</style></abstract><number><style face="normal" font="default" size="100%">4</style></number><volume><style face="normal" font="default" size="100%">15</style></volume></record></records></xml>